(NEW LINE)Warner-Lambert's Lopid
(NEW LINE)Warner-Lambert's Lopid: FDA Endocrinologic & Metabolic Drugs Advisory Committee will review Helsinki Heart Study results in support of a claim for prevention of coronary heart disease on Oct. 17. Meeting will be held at National Institute of Health's Jack Masur Auditorium, beginning at 9:00 a.m. Company announced Sept. 19 that it has received a patent extension for Lopid (gemfibrozil) to Jan. 4, 1993 from the U.S. Patent and Trademark Office under the recently passed trade bill. The patient restoration is contingent on FDA approval of the new claim.
You may also be interested in...
The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.
Adaptive chief medical officer Lance Baldo talked to Medtech Insight about the company's plans to detect prior infection using T-cells obtained from blood samples.
Three new directors at Tenax Therapeutics, and a flurry of CMO and CFO appointments.